Hilde Furberg, Guido Oelkers
Blueprint Genetics has appointed Hilde Furberg as chairman of its board of directors. Furberg previously served as head of rare disease Europe at Sanofi Genzyme. She is also currently an industrial advisor to Investinor and a board member of BerGenBio, Calliditas, and Tappin. Furberg has previously worked at Baxter and Genzyme, and has also been a board member of Probi, Pronova, Clavis, and Algeta.
In addition, Blueprint has appointed Guido Oelkers as a senior advisor. Oelkers currently serves as CEO of Swedish Orphan Biovitirum. He has previously served as CEO of BSN Medical, CEO of Gambro, CEO of Invida, and in a number of executive commercial operations roles in companies such as Nycomed, DKSH Group, and Aventis.
Caroline Loew, Stanley Lapidus, Robert Langer
Glympse Bio has appointed Caroline Loew as president and CEO. Loew previously served as VP, heading R&D strategy and planning at Bristol-Myers Squibb. In addition, she has served in senior roles at Merck and phRMA, where she led teams in drug development, regulatory policy, market access, and commercial operations.
Glympse has also appointed Stanley Lapidus as chairman and Robert Langer to its board of directors. Lapidus has been the founding CEO of four medical technology companies, including Cytyc, Exact Sciences, Helicos, and SynapDx.
Robert Wassman
NeuroPointDx, a division of Stemina Biomarker Discovery, has appointed Robert Wassman as its medical director. Wassman has acted as chief medical officer for several companies in the genetic testing, biomarker discovery, and diagnostic development space. He previously served as CMO of Lineagen from 2015 to 2017, and as CMO of Rosetta Genomics from 2012 to 2015. Wassman has also served as CMO at other companies in the personalized medicine industry over the past 35 years, including Genzyme Genetics, Celula, Ambry Genetics, and Alfigen.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.